Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability. The...
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability. The...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.